The COVID-19 pandemic presented unprecedented challenges for societies around the world. The rapid spread of the virus, combined with its high mortality rate, led to a significant strain on healthcare systems and workers. Governments were forced to implement strict measures to contain the spread of the virus, such as lockdowns, travel restrictions, and mask mandates. These measures, while necessary, had a significant impact on the economy, with many businesses forced to close their doors permanently. The pandemic also highlighted existing inequalities in society, with marginalized communities disproportionately affected by the virus. The development of vaccines provided hope for a return to normalcy, but vaccine hesitancy and distribution challenges presented further hurdles.

During this time of uncertainty, 1health’s mission was to make COVID testing easier, quicker, and more accessible. Nikhil Arun, 1health’s VP of Product + Customer, and his team were responsible for four major innovations that proved to be key during the COVID crisis.

The first at-home saliva test

Nikhil Arun played a crucial role in the fight against the COVID-19 pandemic by spearheading the product team that developed the first at-home COVID saliva test in the United States in partnership with Rutgers University Labs. This was a major breakthrough in the battle against COVID-19 as it allowed individuals to test themselves for the virus without having to rely on healthcare professionals, making the testing process much more accessible and convenient for people in underserved areas.

The at-home COVID saliva test developed by Arun and his team at was particularly important for people who may not have had access to healthcare professionals or testing centers due to various reasons, such as living in remote areas or having a disability that makes it difficult for them to leave their homes. The test was easy to use and allowed individuals to collect their saliva samples in the comfort of their own homes, making the testing process less daunting and more accessible for all.

By developing this innovative testing solution, Arun helped to alleviate some of the major challenges faced during the pandemic, such as the limited availability of testing kits and the long wait times for results. The at-home saliva test allowed people to quickly and easily test themselves for COVID-19, reducing the burden on healthcare systems and helping to slow the spread of the virus.

Testing As a Service

Creating “Testing as a Service” was a game-changer in the fight against COVID-19. Before this innovation, COVID testing was limited to certain healthcare providers or institutions, and the process of implementing testing programs was often complicated and time-consuming. Arun’s idea of offering COVID testing as a service made it possible for any organization to easily deploy a COVID test with their brand on their website. This enabled companies, consumer brands, schools, and government agencies to quickly set up testing programs for their employees, customers, or members.

Such an innovation not only helped to identify and isolate COVID cases early but also helped to prevent the spread of the virus in communities. The ability to offer COVID testing as a service allowed for greater accessibility and flexibility, ensuring that COVID testing was available to a wider range of people across the country. By making COVID testing more widely available, Arun’s innovation played a critical role in slowing the spread of the virus and saving countless lives.

Vaccine management for the underserved

As the COVID-19 vaccine became available, it became clear that there was a significant challenge in getting the vaccine to those who needed it most. This was particularly true for underserved communities, which often lacked access to the resources needed to facilitate vaccine distribution and administration. Nikhil Arun recognized this challenge and took action, developing a tool to manage vaccination administration specifically for underserved communities. This tool enabled these communities to effectively track the distribution and administration of vaccines, ensuring that the most vulnerable members of society were prioritized and protected.

Matt Meyer, the County Executive of New Castle County, praised the work that 1health and Arun did in developing this tool, calling it an “excellent” solution for protecting vulnerable populations. The tool was widely adopted by various organizations and government agencies, making it easier for healthcare professionals to track vaccine distribution and ensure that those who needed the vaccine the most received it in a timely and efficient manner. By providing a much-needed solution to a significant challenge, Arun played a crucial role in the fight against COVID-19, and his innovation helped to save countless lives.

Tracking outbreaks

Nikhil’s team at developed a product to track COVID outbreaks and compliance, which has been utilized by large American companies, schools, counties and the US Air Force. This product allows institutions to operate safely and effectively by tracking COVID outbreaks and ensuring compliance with safety protocols. It has been particularly important for businesses that operate in industries with high levels of customer or employee interaction, such as the food and beverage industry and the transportation industry.

Moreover, Arun has also contributed to cancer prevention and adverse drug reaction prevention through his work at 1health. His team has developed innovative solutions to help identify individuals who may be at risk for developing cancer, such as genetic testing for breast and ovarian cancer. This testing can help individuals take proactive steps to reduce their risk of developing cancer or detect it early, when it is most treatable. In addition, Arun’s team has also developed solutions to help prevent adverse drug reactions, which are a major cause of hospitalizations and deaths in the United States. Their innovative approach to adverse drug reaction prevention involves the use of genetic testing to identify individuals who may be at risk for adverse drug reactions and the development of personalized treatment plans to reduce that risk.

Learn more:

Advertising disclosure: We may receive compensation for some of the links in our stories. Thank you for supporting LA Weekly and our advertisers.